摘要
目的探讨康柏西普联合全视网膜光凝(PRP)治疗缺血型视网膜中央静脉阻塞(CRVO)引起新生血管性青光眼(NVG)的效果及对房水Klotho和Endothelin-1的影响。方法选取2019年12月—2020年12月80例缺血型CRVO引起的NVG(80只眼),根据治疗方法不同分为对照组和研究组,每组40例(40只眼)。对照组采用PRP治疗,研究组采用康柏西普联合PRP治疗。对比两组综合疗效、不良事件及复发情况。比较两组治疗前后眼压和最佳矫正视力(BCVA),房水Klotho、Endothelin-1、血管内皮生长因子(VEGF)、血小板反应蛋白-1(TSP-1)、细胞色素C(CytC)、线粒体融合蛋白1(Mfn1)水平,以及视网膜中央动脉舒张末期血流速度(EDV)、收缩期峰值血流速度(PSA)。结果研究组总有效率高于对照组(P<0.05)。治疗前、治疗后4和8周,两组眼压及房水Endothelin-1、VEGF、TSP-1、CytC水平呈降低趋势,BCVA、房水Klotho和Mfn1水平、视网膜中央动脉EDV和PSA呈升高趋势;且研究组治疗后4、8周上述指标降低和升高程度均优于对照组(P<0.05)。研究组不良事件发生率低于对照组(P<0.05)。两组复发率比较差异无统计学意义(P>0.05)。结论采用康柏西普联合PRP治疗缺血型CRVO引起NVG,能显著提高治疗效果,进一步提高患者视力水平,抑制新生血管生成,改善房水Klotho、Endothelin-1水平。
Objective To investigate the effect of Conbercept combined with panretinal photocoagulation(PRP)in the treatment of neovascular glaucoma(NVG)caused by ischemic central retinal vein occlusion(CRVO)and its effect on Klotho and endothelin-1 in aqueous humor.Methods From December 2019 to December 2020,80 cases of NVG(80 eyes)caused by ischemic CRVO were selected and divided into control group and research group according to different treatment methods,with 40 cases(40 eyes)in each group.The control group was treated with PRP,and the research group was treated with Conbercept combined with PRP.The comprehensive efficacy,adverse events and recurrence of the two groups were compared.The levels of intraocular pressure(IOP),best corrected visual acuity(BCVA),aqueous humor Klotho,endothelin-1,vascular endothelial growth factor(VEGF),thrombospondin-1(TSP-1),cytochrome c(CytC),mitochondrial fusion protein 1(Mfn1),end diastolic blood flow velocity(EDV)and peak systolic blood flow velocity(PSA)of central retinal artery were compared between the two groups before and after treatment.Results The total effective rate of the research group was higher than that of the control group(P<0.05).Before treatment,at 4 and 8 weeks after treatment,the IOP and the levels of endothelin-1,VEGF,TSP-1 and CytC in aqueous humor decreased,while the levels of BCVA,Klotho and Mfn1 in aqueous humor,EDV and PSA in central retinal artery increased;the decrease and increase of the above indexes in the research group were better than those in the control group at 4 and 8 weeks after treatment(P<0.05).The incidence of adverse events in the research group was lower than that in the control group(P<0.05).There was no significant difference in recurrence rate between the two groups(P>0.05).Conclusion Conbercept combined with PRP in the treatment of NVG caused by ischemic CRVO can significantly improve the therapeutic effect,further improve the visual acuity level of patients,inhibit angiogenesis and improve the levels of Klotho and endothelin-1 in aqueous hu
作者
陈雪红
吴子东
庄海容
陈圣文
CHEN Xue-hong;WU Zi-dong;ZHUANG Hai-rong;CHEN Sheng-wen(Department of Ophthalmology,the Second Affiliated Hospital of Hainan Medical University,Haikou,Hainan 570000,China)
出处
《临床误诊误治》
CAS
2022年第5期31-34,共4页
Clinical Misdiagnosis & Mistherapy
基金
海南省卫生计生行业科研项目(18A200169)。
